CLE is an innovative test that records the larynx during intensive treadmill exercise, and analyses the data according to respiratory parameters. This enables researchers to discover abnormalities in the central airways.
Simultaneous external video and audio recordings are made in order to more effectively differentiate exercise-induced asthma from other forms of exercise-induced dyspnoea or exercise-related obstructions of central airways. Diagnosing the obstruction of central airways is quite difficult, and differentiating exercise-induced asthma from other common causes of similar symptoms is not well defined. The ability to properly diagnose patients requires the laryngeal function to be visualized during on-going exercise. Until now, patients were examined via post-exercise laryngoscopy, which not only elevated the rate of panic and negative tests, but also gave limited information regarding what had provoked the laryngeal obstruction since the response was already present when the endoscope was introduced.
The CLE test revolutionises diagnostics in facilitating video-recorded laryngoscopy throughout a complete, maximal exercise test.
Haukeland University Hospital
University of Bergen
Olav Drange Røkesund, Haukeland University Hospital
Thomas Halvorsen, Professor, Haukeland University Hospital
Profitek (manufacturing, delivery and support) and Inventas (design services).
One out of 10 000 children all over the world is born with the rare metabolic disorder phenylketonuria (PKU). Researchers from Bergen develops a treatment against the disorder, and their research are promising.
Every year, 5000 Norwegian men is diagnosed with prostate cancer and approximately 20% of them die. Cryoimmunotherapy is a new treatment for prostate cancer that mobilizes the patient’s own immune system to attack the cancer cells.
UTILE is an ideal platform for actors within the life sciences and health sector to collaborate with each other, to find clustered information, and to have an overview of promising research results that went through extensive evaluation. UTILE will analyse all previously granted Health projects in FP7 and H2020 to identify the research results with the highest potential for exploitation.